by Elizabeth Gourd
The Lancet
Oncology : News: Volume 19, issue 9 PE445, September 01, 2018
Multigene hereditary
cancer panel testing could be used to identify women with an elevated risk of
triple-negative breast cancer as a result of deleterious mutations in five
genes, according to a recent study.
